Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05437159 · ClinicalTrials.gov registry record · NA

Investigating Speech Sequencing in Neurotypical Speakers and Persons With Disordered Speech

A NA study of Stuttering, Developmental and Aphasia, Primary Progressive, sponsored by Boston University Charles River Campus.

Recruiting
Registry status
NA
Development phase
2
Enrollment target
3
Study locations

NCT05437159 is a NA study of Stuttering, Developmental and Aphasia, Primary Progressive that is actively recruiting participants, run by Boston University Charles River Campus. The registered enrollment target is 2 participants, below the 875-participant average among 4 other Stuttering, Developmental trials with a reported enrollment target (100% lower). The trial reports 3 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05437159, a NA study of Stuttering, Developmental and Aphasia, Primary Progressive, is actively recruiting participants, sponsored by Boston University Charles River Campus.

RECRUITING
Registry status
NA
Development phase
2 participants
Enrollment target
3
Study locations

Study Summary

Persistent developmental stuttering affects more than three million people in the United States, and it can have profound adverse effects on quality of life. Despite its prevalence and negative impact, stuttering has resisted explanation and effective treatment, due in large part to a poor understanding of the neural processing impairments underlying the disorder. The overall goal of this study is to improve understanding of the brain mechanisms involved in speech motor planning and how these are disrupted in neurogenic speech disorders, like stuttering. The investigators will do this through an integrated combination of experiments that involve speech production, functional MRI, and non-invasive brain stimulation. The study is designed to test hypotheses regarding the brain processes involved in learning and initiating new speech sound sequences and how those processes compare in persons with persistent developmental stuttering and those with typical speech development. These processes will be studied in both adults and children. Additionally, these processes will be investigated in patients with neurodegenerative speech disorders (primary progressive aphasia) to further inform the investigators understanding of the neural mechanisms that support speech motor sequence learning. Together these experiments will result in an improved account of the brain mechanisms underlying speech production in fluent speakers and individuals who stutter, thereby paving the way for the development of new therapies and technologies for addressing this disorder.

Interventions

  • DEVICE Sham tDCS
  • BEHAVIORAL Learning of non-native phoneme combinations: 6 training sessions
  • BEHAVIORAL Learning of non-native phoneme combinations: 1 training session
  • BEHAVIORAL Learning of novel multisyllabic nonwords
  • DEVICE Anodal tDCS

Study Locations (3)

Massachusetts

  • Massachusetts General Hospital - Boston
  • Boston University - Boston

Michigan

  • University of Michigan - Ann Arbor

Trial Details

FieldValue
Enrollment Target 2 participants
Start Date 2023-04-03
Est. Completion 2026-05
Phase NA

What the Registry Record Tells You About NCT05437159

The ClinicalTrials.gov registry entry for NCT05437159 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 875-participant average among 4 other Stuttering, Developmental trials with a reported enrollment target (100% lower). The listed sponsor is Boston University Charles River Campus, which has 104 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Stuttering, Developmental appearing as the primary indexed condition, and to 5 interventions - of which Sham tDCS is the first listed.

NCT05437159 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, Michigan.

Frequently Asked Questions

What is clinical trial NCT05437159 about?

NCT05437159 is a clinical study titled "Investigating Speech Sequencing in Neurotypical Speakers and Persons With Disordered Speech". Persistent developmental stuttering affects more than three million people in the United States, and it can have profound adverse effects on quality of life. Despite its prevalence and negative impact, stuttering has resisted explanation and effective treatment, due in large part to a poor understan...

What is the current status of trial NCT05437159?

This trial is currently recruiting. It is a NA study. The enrollment target is 2 participants. The study started on 2023-04-03. Estimated completion is 2026-05.

What conditions does trial NCT05437159 study?

This clinical trial studies the following conditions: Stuttering, Developmental, Aphasia, Primary Progressive.

What interventions are being tested in trial NCT05437159?

The interventions under investigation include: Sham tDCS (DEVICE), Learning of non-native phoneme combinations: 6 training sessions (BEHAVIORAL), Learning of non-native phoneme combinations: 1 training session (BEHAVIORAL), Learning of novel multisyllabic nonwords (BEHAVIORAL), Anodal tDCS (DEVICE).

Who is sponsoring clinical trial NCT05437159?

This trial is sponsored by Boston University Charles River Campus, which has 104 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05437159 being conducted?

This trial has 3 study locations across Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Stuttering, Developmental

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.